Genetic analysis links GLP-1 agonism to pancreatitis risk and sarcopenia in large cohorts
Genetic data link GLP-1 drugs to pancreatitis and muscle loss risks
A Mendelian randomization study of over one million participants suggests GLP-1 receptor agonists causally reduce diabetes risk but may incr…
Genetic analysis suggests GLP-1 receptor agonists may increase pancreatitis risk and muscle loss, while lowering blood sugar and diabetes ri…
Narrative review examines metabolic syndrome and novel agents in kidney transplant recipients
Kidney transplant patients face high metabolic risks and rejection
This narrative review addresses antibody-mediated rejection and metabolic syndrome in kidney transplantation recipients. The authors note th…
About half of kidney transplant recipients develop metabolic problems within a year, while antibody-mediated rejection remains a major cause…
Meta-analysis of Mendelian randomization suggests GLP-1 receptor agonism lowers vascular dementia risk
Genetic data suggests GLP-1 drugs may lower vascular dementia risk
This meta-analysis of Mendelian randomization studies evaluated the association between GLP-1 receptor agonism and dementia risk using genet…
New genetic evidence hints that GLP-1 receptor agonists might lower the risk of vascular dementia, but results for Alzheimer's disease remai…
Meta-analysis of GLP-1 agonists for Parkinson's disease motor symptoms shows limited benefit
A recent review found no clear benefit for Parkinsons disease patients taking GLP-1 drugs compared to placebo
This meta-analysis of randomized trials examined GLP-1 receptor agonists for Parkinson's disease. It found no statistically significant impr…
A new analysis of studies shows GLP-1 drugs did not improve movement or daily life for people with Parkinsons disease. While quality of life…
GLP-1 receptor agonists show greater weight loss in women than men across multiple trials
Women Lose More Weight on GLP-1 Drugs Than Men Do
This systematic review and meta-analysis examined weight changes among adults with obesity, diabetes, or cardiovascular disease treated with…
• Women lose 11% weight versus 7% for men on these drugs • Helps adults using Wegovy Ozempic and similar weight loss medications • Works sam…
Meta-analysis finds GLP-1RA plus SGLT2i reduces UACR in type 2 diabetes with kidney disease
Combining two diabetes drugs protects kidneys better than using just one alone
This systematic review and meta-analysis of 1974 adults with type 2 diabetes and diabetic kidney disease found that combination therapy with…
Combining two common diabetes drugs offers better kidney protection than taking just one alone for people with type 2 diabetes
Narrative review discusses pharmacological and lifestyle interventions for type 2 diabetes and psychological health
New hope for diabetes patients struggling with anxiety and depression
This narrative review examines the relationship between type 2 diabetes and conditions such as anxiety, depression, and cognitive impairment…
Diabetes drugs that control blood sugar might also help improve mood and reduce anxiety for patients living with the condition.
GZR18 showed weight loss in Chinese adults with overweight or obesity in a phase 1b/2a trial
New Drug Cuts Weight by Nearly 20% in Just 35 Weeks
In this randomized, placebo-controlled phase 1b/2a trial, 60 Chinese adults with overweight or obesity received GZR18 or placebo.
This new treatment shows huge promise for helping people reach their weight goals without daily pills.
Narrative review examines multidisciplinary strategies for metabolic syndrome in bipolar disorder
Half of Bipolar Patients Face Hidden Heart Risks
This narrative review explores multidisciplinary monitoring and treatment strategies, including lifestyle and pharmacological approaches, fo…
Imagine living with bipolar disorder. You manage your mood swings with medication and therapy.
GLP-1 receptor agonists associated with lower mortality in HFrEF on GDMT
Heart Failure Patients Cut Death Risk With Common Diabetes Drug
In a retrospective, multicenter cohort study of 1,518 adults with HFrEF on guideline-directed therapy, GLP-1 receptor agonist use was associ…
Adding a common diabetes medication to standard heart failure treatment may significantly lower death rates.
Monitoring report on US GLP-1 RA prescribing trends shows increased oral semaglutide use
Why are so many people getting new diabetes and weight-loss drugs?
This monitoring report analyzes real-world US electronic health record data from Truveta on GLP-1 RA prescribing.
Prescriptions for diabetes and weight-loss drugs jumped sharply in the US after a new oral pill was approved, with first-time use rising ove…
Narrative review conceptualizes CVD as systemic immune–metabolic–inflammatory disease
Review suggests immune and metabolic factors drive cardiovascular disease progression
This narrative review synthesizes evidence on cardiovascular disease as a systemic immune–metabolic–inflammatory condition.
Immune and metabolic factors actively drive heart disease progression, offering new ways to assess risk and tailor prevention strategies.